JAMA Network Home
Sign In
Review

Liquid Biopsies for Cancer

JAMA 10.1001/jama.2026.13898

August 10, 2026 at 11:00 AM EDT

Read the full article

ctDNA, consisting of small DNA fragments from cancer cells that can be analyzed in human blood, can help clinicians monitor cancer progression, detect minimal residual cancer, and identify genetic variants that may help guide treatment decisions. Use of ctDNA may help select best treatment and timing of therapy for a patient with cancer, but optimal clinical applications remain unclear.

Corresponding Author: Ben H. Park, MD, PhD, Vanderbilt-Ingram Cancer Center, 2220 Pierce Ave, PRB 798C, Nashville, TN 37232 (ben.h.park@vumc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.13898?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081026

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks